Study of SHR2150 (TLR7 Agonist) in Combination With Chemotherapy Plus PD-1 or CD47 Antibody in Subjects With Unresectable/ Metastatic Solid Tumors
Clinical trial NCT04588324 · UNKNOWN
Trial details
- NCT number
- NCT04588324
- Sponsor
- Chinese PLA General Hospital
- Status
- UNKNOWN
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2020-10-10
- Primary completion
- 2021-11-30
- Enrollment
- 50
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.